Titlebook: Regulation of the Pharmaceutical Industry; John Abraham (Professor of Sociology and Co-direct Book 2003 Palgrave Macmillan, a division of

nettle

擺動(dòng)

Sales Licensing Documentation and Trade Secrecy: the case of NorplantR Contraceptives,quality and rationally used. Vital drugs should be available and accessible at a reasonable cost for the individual and for the society. Rational use of drugs implies that, in addition to the properties of the drugs, there is adequate information to select the most appropriate drug or no drug at all

數(shù)量

Biological Medicines in the Age of Biotech: Public Policy Issues,class of medicines known as ‘biologicals’. Take, for example, blood and blood products. They are an essential and life-saving component of everyday medical practice. But the AIDS epidemic provided painful evidence of how disease could be transmitted by donated blood or products made from it, such as

ingestion

Cpap155

保守

Regulation for Ethical Purposes: Medical Research on Humans,ich began as very unregulated regulators and have become highly regulatory and increasingly regulated themselves. I conclude with some reflections on future developments, taking the draft European Directive on clinical trials into account.

松馳

The Limitations of Current Ethical Regulations,rug trials in particular. The principle of informed consent, is central to these guidelines and has come to be seen as ‘the ethical solution’ to prevent the exploitation and abuse of human subjects. I present a critical examination of the central role accorded to this principle and challenge its ema

執(zhí)

Mergers and Joint Ventures in the Pharmaceutical Industry,s have had on the treatment of all joint ventures including those in the pharmaceutical industry. It also provides some insight into the way in which the European Commission and the UK competition authorities are likely to approach the definition of relevant markets in future mergers and joint ventu

PANIC

bypass